These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 1535677)

  • 21. Modulation of endothelin production and metabolism in guinea-pig tracheal epithelial cells by peptidase inhibitors.
    Yang Q; Battistini B; D'Orléans-Juste P; Jeng AY; Sirois P
    Am J Respir Crit Care Med; 1997 Jun; 155(6):1884-9. PubMed ID: 9196090
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Marked difference between angiotensin-converting enzyme and neutral endopeptidase inhibition in vivo by a dual inhibitor of both enzymes.
    Anastasopoulos F; Leung R; Kladis A; James GM; Briscoe TA; Gorski TP; Campbell DJ
    J Pharmacol Exp Ther; 1998 Mar; 284(3):799-805. PubMed ID: 9495836
    [TBL] [Abstract][Full Text] [Related]  

  • 23. CGS 34043: a non-peptidic, potent and long-acting dual inhibitor of endothelin converting enzyme-1 and neutral endopeptidase 24.11.
    Trapani AJ; De Lombaert S; Beil ME; Bruseo CW; Savage P; Chou M; Jeng AY
    Life Sci; 2000; 67(9):1025-33. PubMed ID: 10954036
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prolonged neutral endopeptidase inhibition in heart failure.
    Helin K; Tikkanen I; Tikkanen T; Saijonmaa O; Sybertz EJ; Vemulapalli S; Sariola H; Fyhrquist F
    Eur J Pharmacol; 1991 May; 198(1):23-30. PubMed ID: 1655477
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Modulation of functionally active endothelin-converting enzyme by chronic neutral endopeptidase inhibition in experimental atherosclerosis.
    Grantham JA; Schirger JA; Wennberg PW; Sandberg S; Heublein DM; Subkowski T; Burnett JC
    Circulation; 2000 Apr; 101(16):1976-81. PubMed ID: 10779465
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Vascular A10 cell membranes contain an endothelin metabolizing neutral endopeptidase.
    Dickinson KE; Tymiak AA; Cohen RB; Liu EC; Webb ML; Hedberg A
    Biochem Biophys Res Commun; 1991 Apr; 176(1):423-30. PubMed ID: 2018530
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Role of the neutral endopeptidase 24.11 in the conversion of big endothelins in guinea-pig lung parenchyma.
    Lebel N; D'Orléans-Juste P; Fournier A; Sirois P
    Br J Pharmacol; 1996 Jan; 117(1):184-8. PubMed ID: 8825361
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Rat vascular tissue contains a neutral endopeptidase capable of degrading atrial natriuretic peptide.
    Tamburini PP; Koehn JA; Gilligan JP; Charles D; Palmesino RA; Sharif R; McMartin C; Erion MD; Miller MJ
    J Pharmacol Exp Ther; 1989 Dec; 251(3):956-61. PubMed ID: 2532252
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Neutral endopeptidase inhibition potentiates the natriuretic actions of adrenomedullin.
    Lisy O; Jougasaki M; Schirger JA; Chen HH; Barclay PT; Burnett JC
    Am J Physiol; 1998 Sep; 275(3):F410-4. PubMed ID: 9729514
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Evidence for metalloprotease involvement in the in vivo effects of big endothelin 1.
    Pollock DM; Opgenorth TJ
    Am J Physiol; 1991 Jul; 261(1 Pt 2):R257-63. PubMed ID: 1650147
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Role of neutral endopeptidase 24.11 in AV fistular rat model of heart failure.
    Wegner M; Hirth-Dietrich C; Stasch JP
    Cardiovasc Res; 1996 Jun; 31(6):891-8. PubMed ID: 8759244
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Localization and characterization of neutral metalloendopeptidase (EC 3.4.24.11), the degradative enzyme for atrial natriuretic peptide, in rat kidney using a radioiodinated neutral metalloendopeptidase inhibitor.
    Kanazawa M; Casley DJ; Sybertz EJ; Haslanger MF; Johnston CI
    J Pharmacol Exp Ther; 1992 Jun; 261(3):1231-7. PubMed ID: 1534841
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The effect of the neutral endopeptidase inhibitor drug, candoxatril, on circulating levels of two of the most potent vasoactive peptides.
    McDowell G; Coutie W; Shaw C; Buchanan KD; Struthers AD; Nicholls DP
    Br J Clin Pharmacol; 1997 Mar; 43(3):329-32. PubMed ID: 9088591
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Antihypertensive activity during inhibition of neutral endopeptidase and angiotensin converting enzyme.
    Seymour AA; Swerdel JN; Abboa-Offei B
    J Cardiovasc Pharmacol; 1991 Mar; 17(3):456-65. PubMed ID: 1711608
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Increased renal endothelin production in rats with reduced renal mass.
    Benigni A; Perico N; Gaspari F; Zoja C; Bellizzi L; Gabanelli M; Remuzzi G
    Am J Physiol; 1991 Mar; 260(3 Pt 2):F331-9. PubMed ID: 2000950
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Possible regulation of atrial natriuretic factor by neutral endopeptidase 24.11 and clearance receptors.
    Seymour AA; Norman JA; Asaad MM; Fennell SA; Abboa-Offei B; Little DK; Kratunis VJ; Delaney NG; Hunt JT; Di Donato G
    J Pharmacol Exp Ther; 1991 Mar; 256(3):1002-9. PubMed ID: 1826031
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Dual inhibition of neutral endopeptidase and angiotensin-converting enzyme in rats with hypertension and diabetes mellitus.
    Tikkanen T; Tikkanen I; Rockell MD; Allen TJ; Johnston CI; Cooper ME; Burrell LM
    Hypertension; 1998 Oct; 32(4):778-85. PubMed ID: 9774379
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pharmacologic profile of CGS 24128, a potent, long-acting inhibitor of neutral endopeptidase 24.11.
    Trapani AJ; Beil ME; Coté DT; de Lombaert S; Erion MD; Gerlock TE; Ghai RD; Hopkins MF; Peppard JV; Webb RL
    J Cardiovasc Pharmacol; 1994 Mar; 23(3):358-64. PubMed ID: 7515977
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pharmacological properties of CGS 35066, a potent and selective endothelin-converting enzyme inhibitor, in conscious rats.
    Trapani AJ; Beil ME; Bruseo CW; De Lombaert S; Jeng AY
    J Cardiovasc Pharmacol; 2000 Nov; 36(5 Suppl 1):S40-3. PubMed ID: 11078331
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Synthetic inhibitors of endopeptidase EC 3.4.24.15: potency and stability in vitro and in vivo.
    Lew RA; Tomoda F; Evans RG; Lakat L; Boublik JH; Pipolo LA; Smith AI
    Br J Pharmacol; 1996 Jul; 118(5):1269-77. PubMed ID: 8818353
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.